glp 1 agonist clinical trials Obesity GLP-1 Agonists - What is

Public reimbursement accounts for only 15% of the market, primarily covering patients with severe obesity and documented metabolic complications

The Lancet, 390 (10103): 16641675

Online accounted for a significant market share in 2023, and Hospital Pharmacies is expected to hold a dominant position in the forecast period owing to as it plays a critical role in ensuring that patients receiving inpatient care or undergoing medical procedures have uninterrupted access to GLP-1 receptor agonists

[1] Research [edit] Preclinical studies suggest that retatrutide may influence obesity-associated cancer progression

Inoue, T

doi: 10.4140/TCP.n.2016.685